Having in the mind that a key event in the progression of BC is the development of lymph node metastases, it is very important to determine prognostic benefit of standard and new molecular markers (ER, HER2, EZH2, CD44) on the occurrence of metastatic disease. Here, ERBB2 is linked to metastatic malignant neoplasm in the lymph nodes.